Biocon Limited (BOM:532523)
India · Delayed Price · Currency is INR 370.10
-9.60 (-2.53%)
At close: Mar 27, 2026
Biocon Revenue
Biocon had revenue of 41.73B INR in the quarter ending December 31, 2025, with 9.20% growth. This brings the company's revenue in the last twelve months to 168.27B, up 13.99% year-over-year. In the fiscal year ending March 31, 2025, Biocon had annual revenue of 152.62B with 3.43% growth.
Revenue (ttm)
168.27B
Revenue Growth
+13.99%
P/S Ratio
3.56
Revenue / Employee
10.25M
Employees
16,420
Market Cap
598.96B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 152.62B | 5.06B | 3.43% |
| Mar 31, 2024 | 147.56B | 35.82B | 32.05% |
| Mar 31, 2023 | 111.74B | 29.90B | 36.54% |
| Mar 31, 2022 | 81.84B | 10.41B | 14.57% |
| Mar 31, 2021 | 71.43B | 8.43B | 13.37% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aarti Drugs | 25.22B |
| Hester Biosciences | 3.16B |
| Titan Biotech | 1.93B |
| Zenotech Laboratories | 419.33M |
| Bharat Immunologicals & Biologicals Corporation | 76.50M |
| Genesis IBRC India | 36.67M |
| Hindustan Bio Sciences | 11.35M |
| Transgene Biotek | 2.33M |
Biocon News
- 2 days ago - Biocon announces changes in trustees for employee welfare trust - Business Upturn
- 2 days ago - Biocon appoints Shreehas Tambe as CEO and Managing Director effective April 2026 - Business Upturn
- 6 days ago - St Patrick’s Day celebrated in Bengaluru with focus on India-Ireland ties - The Times of India
- 10 days ago - Pharma sector stocks fall today, March 19: Biocon down 2.33%, Laurus Labs falls 2.29%, Glenmark Pharma drops 2% - Business Upturn
- 17 days ago - Biocon receives U.S. FDA approval for Liraglutide injection - Business Upturn
- 4 weeks ago - Stocks to watch today, February 25: Hindalco, Biocon, Power Grid, Lupin, IRFC and more - Business Upturn
- 5 weeks ago - Pharma sector stocks today, Feb 20: Novartis India rally 20%, Biocon jumps 1.36%, Alembic rises 1.11% - Business Upturn
- 6 weeks ago - Biocon Ltd (BOM:532523) Q3 2026 Earnings Call Highlights: Strong Revenue Growth Amidst ... - GuruFocus